T-DXd was first FDA-approved for this indication in 2019, and it has since also been approved for HER2-low metastatic breast cancer, HER2-positive advanced gastric cancer, and HER2-mutant metastatic non-small-cell lung cancer. This evidence concerns the gene ERBB2 and breast carcinoma.